These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9792286)

  • 1. Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene.
    Casonato A; Gaucher C; Pontara E; Zucchetto A; Zerbinati P; Mazurier C; Girolami A
    Br J Haematol; 1998 Oct; 103(1):39-41. PubMed ID: 9792286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient with von Willebrand's disease characterized by a compound heterozygosity for a substitution of Arg854 by Gln in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF allele.
    Peerlinck K; Eikenboom JC; Ploos Van Amstel HK; Sangtawesin W; Arnout J; Reitsma PH; Vermylen J; Briët E
    Br J Haematol; 1992 Mar; 80(3):358-63. PubMed ID: 1581215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant.
    Casonato A; Sartorello F; Cattini MG; Pontara E; Soldera C; Bertomoro A; Girolami A
    Blood; 2003 Jan; 101(1):151-6. PubMed ID: 12393698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
    J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of the Arg91Gln substitution in the factor VIII binding domain of von Willebrand factor demonstrates variable phenotypic expression.
    Lavergne JM; Piao Y; Ribba AS; Girma JP; Siguret V; Piétu G; Boyer-Neumann C; Schandelong A; Bahnak BR; Meyer D
    Thromb Haemost; 1993 Oct; 70(4):691-6. PubMed ID: 8115998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease.
    Gaucher C; Mercier B; Jorieux S; Oufkir D; Mazurier C
    Br J Haematol; 1991 Aug; 78(4):506-14. PubMed ID: 1832934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization.
    Jorieux S; Gaucher C; Goudemand J; Mazurier C
    Blood; 1998 Dec; 92(12):4663-70. PubMed ID: 9845532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
    Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
    Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A common frameshift mutation in von Willebrand factor does not alter mRNA stability but interferes with normal propeptide processing.
    Mohlke KL; Nichols WC; Rehemtulla A; Kaufman RJ; Fagerström HM; Ritvanen KL; Kekomăki R; Ginsburg D
    Br J Haematol; 1996 Oct; 95(1):184-91. PubMed ID: 8857958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
    Kroner PA; Friedman KD; Fahs SA; Scott JP; Montgomery RR
    J Biol Chem; 1991 Oct; 266(29):19146-9. PubMed ID: 1918030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
    Hilbert L; Nurden P; Caron C; Nurden AT; Goudemand J; Meyer D; Fressinaud E; Mazurier C;
    Thromb Haemost; 2006 Sep; 96(3):290-4. PubMed ID: 16953269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD.
    Siguret V; Lavergne JM; Chérel G; Boyer-Neumann C; Ribba AS; Bahnak BR; Meyer D; Piétu G
    Hum Genet; 1994 Feb; 93(2):95-102. PubMed ID: 7906671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
    Eikenboom JC; Matsushita T; Reitsma PH; Tuley EA; Castaman G; Briët E; Sadler JE
    Blood; 1996 Oct; 88(7):2433-41. PubMed ID: 8839833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: definite evidence for the non-penetrance of the C2362F mutation.
    Castaman G; Bertoncello K; Bernardi M; Eikenboom JC; Budde U; Rodeghiero F
    Am J Hematol; 2007 May; 82(5):376-80. PubMed ID: 17109387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques.
    Nesbitt IM; Goodeve AC; Guilliatt AM; Makris M; Preston FE; Peake IR
    Thromb Haemost; 1996 Jun; 75(6):959-64. PubMed ID: 8822593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.